Hypercalcemia of Malignancy: Time to Pull the Brakes
Abstract Hypercalcemia of malignancy (HOM) is usually seen in advanced stage and carries a poor prognosis. Survival outcomes are dismal and most of the patients are unable to receive subsequent definite anti-cancer therapy. There is lack of any retrospective or prospective data regarding hypercalcem...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Sundriyal, Deepak [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Anmerkung: |
© Indian Association of Surgical Oncology 2020 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Indian Journal of Surgical Oncology - Springer-Verlag, 2010, 13(2020), 1 vom: 11. Juni, Seite 28-32 |
|---|---|
| Übergeordnetes Werk: |
volume:13 ; year:2020 ; number:1 ; day:11 ; month:06 ; pages:28-32 |
| Links: |
|---|
| DOI / URN: |
10.1007/s13193-020-01131-5 |
|---|
| Katalog-ID: |
SPR046686487 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR046686487 | ||
| 003 | DE-627 | ||
| 005 | 20230507151028.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220407s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13193-020-01131-5 |2 doi | |
| 035 | |a (DE-627)SPR046686487 | ||
| 035 | |a (SPR)s13193-020-01131-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sundriyal, Deepak |e verfasserin |0 (orcid)0000-0002-6378-7694 |4 aut | |
| 245 | 1 | 0 | |a Hypercalcemia of Malignancy: Time to Pull the Brakes |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Indian Association of Surgical Oncology 2020 | ||
| 520 | |a Abstract Hypercalcemia of malignancy (HOM) is usually seen in advanced stage and carries a poor prognosis. Survival outcomes are dismal and most of the patients are unable to receive subsequent definite anti-cancer therapy. There is lack of any retrospective or prospective data regarding hypercalcemia of malignancy in Indian population. We aim to describe survival outcomes in hypercalcemia associated with solid organ malignancies. Forty-five patients diagnosed with HOM associated with solid organ malignancies were included in the study. Patients were followed up till death. Clinical features and survival outcomes were noted. Squamous cell carcinoma of head and neck region and lung comprised most of the cases associated with HOM. Most of the patients presented with poor performance status. Median overall survival (OS) was 20 days (2–78 days). Median OS was 35 days (9–58 days) in those who received definite anti-cancer therapy. Four-week mortality rate was estimated as 59.5%, while this increased to 75.7% within 6 weeks from the diagnosis of hypercalcemia. Survival outcomes are poor after the diagnosis of hypercalcemia in cancer patients. Best supportive care including hospice care should be strongly considered at this point of time instead of definite systemic anti-cancer therapy. | ||
| 650 | 4 | |a Hypercalcemia of malignancy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Bisphosphonate therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Squamous cell carcinoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Best supportive care |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Arya, Lima |4 aut | |
| 700 | 1 | |a Saha, Rajat |4 aut | |
| 700 | 1 | |a Walia, Meenu |4 aut | |
| 700 | 1 | |a Nayak, Priya P |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Indian Journal of Surgical Oncology |d Springer-Verlag, 2010 |g 13(2020), 1 vom: 11. Juni, Seite 28-32 |w (DE-627)SPR030797241 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2020 |g number:1 |g day:11 |g month:06 |g pages:28-32 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13193-020-01131-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2020 |e 1 |b 11 |c 06 |h 28-32 | ||
| author_variant |
d s ds l a la r s rs m w mw p p n pp ppn |
|---|---|
| matchkey_str |
sundriyaldeepakaryalimasaharajatwaliamee:2020----:yecleiomlgactmtp |
| hierarchy_sort_str |
2020 |
| publishDate |
2020 |
| allfields |
10.1007/s13193-020-01131-5 doi (DE-627)SPR046686487 (SPR)s13193-020-01131-5-e DE-627 ger DE-627 rakwb eng Sundriyal, Deepak verfasserin (orcid)0000-0002-6378-7694 aut Hypercalcemia of Malignancy: Time to Pull the Brakes 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2020 Abstract Hypercalcemia of malignancy (HOM) is usually seen in advanced stage and carries a poor prognosis. Survival outcomes are dismal and most of the patients are unable to receive subsequent definite anti-cancer therapy. There is lack of any retrospective or prospective data regarding hypercalcemia of malignancy in Indian population. We aim to describe survival outcomes in hypercalcemia associated with solid organ malignancies. Forty-five patients diagnosed with HOM associated with solid organ malignancies were included in the study. Patients were followed up till death. Clinical features and survival outcomes were noted. Squamous cell carcinoma of head and neck region and lung comprised most of the cases associated with HOM. Most of the patients presented with poor performance status. Median overall survival (OS) was 20 days (2–78 days). Median OS was 35 days (9–58 days) in those who received definite anti-cancer therapy. Four-week mortality rate was estimated as 59.5%, while this increased to 75.7% within 6 weeks from the diagnosis of hypercalcemia. Survival outcomes are poor after the diagnosis of hypercalcemia in cancer patients. Best supportive care including hospice care should be strongly considered at this point of time instead of definite systemic anti-cancer therapy. Hypercalcemia of malignancy (dpeaa)DE-He213 Bisphosphonate therapy (dpeaa)DE-He213 Squamous cell carcinoma (dpeaa)DE-He213 Best supportive care (dpeaa)DE-He213 Arya, Lima aut Saha, Rajat aut Walia, Meenu aut Nayak, Priya P aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 13(2020), 1 vom: 11. Juni, Seite 28-32 (DE-627)SPR030797241 nnns volume:13 year:2020 number:1 day:11 month:06 pages:28-32 https://dx.doi.org/10.1007/s13193-020-01131-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 13 2020 1 11 06 28-32 |
| spelling |
10.1007/s13193-020-01131-5 doi (DE-627)SPR046686487 (SPR)s13193-020-01131-5-e DE-627 ger DE-627 rakwb eng Sundriyal, Deepak verfasserin (orcid)0000-0002-6378-7694 aut Hypercalcemia of Malignancy: Time to Pull the Brakes 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2020 Abstract Hypercalcemia of malignancy (HOM) is usually seen in advanced stage and carries a poor prognosis. Survival outcomes are dismal and most of the patients are unable to receive subsequent definite anti-cancer therapy. There is lack of any retrospective or prospective data regarding hypercalcemia of malignancy in Indian population. We aim to describe survival outcomes in hypercalcemia associated with solid organ malignancies. Forty-five patients diagnosed with HOM associated with solid organ malignancies were included in the study. Patients were followed up till death. Clinical features and survival outcomes were noted. Squamous cell carcinoma of head and neck region and lung comprised most of the cases associated with HOM. Most of the patients presented with poor performance status. Median overall survival (OS) was 20 days (2–78 days). Median OS was 35 days (9–58 days) in those who received definite anti-cancer therapy. Four-week mortality rate was estimated as 59.5%, while this increased to 75.7% within 6 weeks from the diagnosis of hypercalcemia. Survival outcomes are poor after the diagnosis of hypercalcemia in cancer patients. Best supportive care including hospice care should be strongly considered at this point of time instead of definite systemic anti-cancer therapy. Hypercalcemia of malignancy (dpeaa)DE-He213 Bisphosphonate therapy (dpeaa)DE-He213 Squamous cell carcinoma (dpeaa)DE-He213 Best supportive care (dpeaa)DE-He213 Arya, Lima aut Saha, Rajat aut Walia, Meenu aut Nayak, Priya P aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 13(2020), 1 vom: 11. Juni, Seite 28-32 (DE-627)SPR030797241 nnns volume:13 year:2020 number:1 day:11 month:06 pages:28-32 https://dx.doi.org/10.1007/s13193-020-01131-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 13 2020 1 11 06 28-32 |
| allfields_unstemmed |
10.1007/s13193-020-01131-5 doi (DE-627)SPR046686487 (SPR)s13193-020-01131-5-e DE-627 ger DE-627 rakwb eng Sundriyal, Deepak verfasserin (orcid)0000-0002-6378-7694 aut Hypercalcemia of Malignancy: Time to Pull the Brakes 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2020 Abstract Hypercalcemia of malignancy (HOM) is usually seen in advanced stage and carries a poor prognosis. Survival outcomes are dismal and most of the patients are unable to receive subsequent definite anti-cancer therapy. There is lack of any retrospective or prospective data regarding hypercalcemia of malignancy in Indian population. We aim to describe survival outcomes in hypercalcemia associated with solid organ malignancies. Forty-five patients diagnosed with HOM associated with solid organ malignancies were included in the study. Patients were followed up till death. Clinical features and survival outcomes were noted. Squamous cell carcinoma of head and neck region and lung comprised most of the cases associated with HOM. Most of the patients presented with poor performance status. Median overall survival (OS) was 20 days (2–78 days). Median OS was 35 days (9–58 days) in those who received definite anti-cancer therapy. Four-week mortality rate was estimated as 59.5%, while this increased to 75.7% within 6 weeks from the diagnosis of hypercalcemia. Survival outcomes are poor after the diagnosis of hypercalcemia in cancer patients. Best supportive care including hospice care should be strongly considered at this point of time instead of definite systemic anti-cancer therapy. Hypercalcemia of malignancy (dpeaa)DE-He213 Bisphosphonate therapy (dpeaa)DE-He213 Squamous cell carcinoma (dpeaa)DE-He213 Best supportive care (dpeaa)DE-He213 Arya, Lima aut Saha, Rajat aut Walia, Meenu aut Nayak, Priya P aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 13(2020), 1 vom: 11. Juni, Seite 28-32 (DE-627)SPR030797241 nnns volume:13 year:2020 number:1 day:11 month:06 pages:28-32 https://dx.doi.org/10.1007/s13193-020-01131-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 13 2020 1 11 06 28-32 |
| allfieldsGer |
10.1007/s13193-020-01131-5 doi (DE-627)SPR046686487 (SPR)s13193-020-01131-5-e DE-627 ger DE-627 rakwb eng Sundriyal, Deepak verfasserin (orcid)0000-0002-6378-7694 aut Hypercalcemia of Malignancy: Time to Pull the Brakes 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2020 Abstract Hypercalcemia of malignancy (HOM) is usually seen in advanced stage and carries a poor prognosis. Survival outcomes are dismal and most of the patients are unable to receive subsequent definite anti-cancer therapy. There is lack of any retrospective or prospective data regarding hypercalcemia of malignancy in Indian population. We aim to describe survival outcomes in hypercalcemia associated with solid organ malignancies. Forty-five patients diagnosed with HOM associated with solid organ malignancies were included in the study. Patients were followed up till death. Clinical features and survival outcomes were noted. Squamous cell carcinoma of head and neck region and lung comprised most of the cases associated with HOM. Most of the patients presented with poor performance status. Median overall survival (OS) was 20 days (2–78 days). Median OS was 35 days (9–58 days) in those who received definite anti-cancer therapy. Four-week mortality rate was estimated as 59.5%, while this increased to 75.7% within 6 weeks from the diagnosis of hypercalcemia. Survival outcomes are poor after the diagnosis of hypercalcemia in cancer patients. Best supportive care including hospice care should be strongly considered at this point of time instead of definite systemic anti-cancer therapy. Hypercalcemia of malignancy (dpeaa)DE-He213 Bisphosphonate therapy (dpeaa)DE-He213 Squamous cell carcinoma (dpeaa)DE-He213 Best supportive care (dpeaa)DE-He213 Arya, Lima aut Saha, Rajat aut Walia, Meenu aut Nayak, Priya P aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 13(2020), 1 vom: 11. Juni, Seite 28-32 (DE-627)SPR030797241 nnns volume:13 year:2020 number:1 day:11 month:06 pages:28-32 https://dx.doi.org/10.1007/s13193-020-01131-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 13 2020 1 11 06 28-32 |
| allfieldsSound |
10.1007/s13193-020-01131-5 doi (DE-627)SPR046686487 (SPR)s13193-020-01131-5-e DE-627 ger DE-627 rakwb eng Sundriyal, Deepak verfasserin (orcid)0000-0002-6378-7694 aut Hypercalcemia of Malignancy: Time to Pull the Brakes 2020 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Indian Association of Surgical Oncology 2020 Abstract Hypercalcemia of malignancy (HOM) is usually seen in advanced stage and carries a poor prognosis. Survival outcomes are dismal and most of the patients are unable to receive subsequent definite anti-cancer therapy. There is lack of any retrospective or prospective data regarding hypercalcemia of malignancy in Indian population. We aim to describe survival outcomes in hypercalcemia associated with solid organ malignancies. Forty-five patients diagnosed with HOM associated with solid organ malignancies were included in the study. Patients were followed up till death. Clinical features and survival outcomes were noted. Squamous cell carcinoma of head and neck region and lung comprised most of the cases associated with HOM. Most of the patients presented with poor performance status. Median overall survival (OS) was 20 days (2–78 days). Median OS was 35 days (9–58 days) in those who received definite anti-cancer therapy. Four-week mortality rate was estimated as 59.5%, while this increased to 75.7% within 6 weeks from the diagnosis of hypercalcemia. Survival outcomes are poor after the diagnosis of hypercalcemia in cancer patients. Best supportive care including hospice care should be strongly considered at this point of time instead of definite systemic anti-cancer therapy. Hypercalcemia of malignancy (dpeaa)DE-He213 Bisphosphonate therapy (dpeaa)DE-He213 Squamous cell carcinoma (dpeaa)DE-He213 Best supportive care (dpeaa)DE-He213 Arya, Lima aut Saha, Rajat aut Walia, Meenu aut Nayak, Priya P aut Enthalten in Indian Journal of Surgical Oncology Springer-Verlag, 2010 13(2020), 1 vom: 11. Juni, Seite 28-32 (DE-627)SPR030797241 nnns volume:13 year:2020 number:1 day:11 month:06 pages:28-32 https://dx.doi.org/10.1007/s13193-020-01131-5 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 13 2020 1 11 06 28-32 |
| language |
English |
| source |
Enthalten in Indian Journal of Surgical Oncology 13(2020), 1 vom: 11. Juni, Seite 28-32 volume:13 year:2020 number:1 day:11 month:06 pages:28-32 |
| sourceStr |
Enthalten in Indian Journal of Surgical Oncology 13(2020), 1 vom: 11. Juni, Seite 28-32 volume:13 year:2020 number:1 day:11 month:06 pages:28-32 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Hypercalcemia of malignancy Bisphosphonate therapy Squamous cell carcinoma Best supportive care |
| isfreeaccess_bool |
false |
| container_title |
Indian Journal of Surgical Oncology |
| authorswithroles_txt_mv |
Sundriyal, Deepak @@aut@@ Arya, Lima @@aut@@ Saha, Rajat @@aut@@ Walia, Meenu @@aut@@ Nayak, Priya P @@aut@@ |
| publishDateDaySort_date |
2020-06-11T00:00:00Z |
| hierarchy_top_id |
SPR030797241 |
| id |
SPR046686487 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR046686487</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230507151028.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220407s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13193-020-01131-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR046686487</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13193-020-01131-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sundriyal, Deepak</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-6378-7694</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hypercalcemia of Malignancy: Time to Pull the Brakes</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Indian Association of Surgical Oncology 2020</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Hypercalcemia of malignancy (HOM) is usually seen in advanced stage and carries a poor prognosis. Survival outcomes are dismal and most of the patients are unable to receive subsequent definite anti-cancer therapy. There is lack of any retrospective or prospective data regarding hypercalcemia of malignancy in Indian population. We aim to describe survival outcomes in hypercalcemia associated with solid organ malignancies. Forty-five patients diagnosed with HOM associated with solid organ malignancies were included in the study. Patients were followed up till death. Clinical features and survival outcomes were noted. Squamous cell carcinoma of head and neck region and lung comprised most of the cases associated with HOM. Most of the patients presented with poor performance status. Median overall survival (OS) was 20 days (2–78 days). Median OS was 35 days (9–58 days) in those who received definite anti-cancer therapy. Four-week mortality rate was estimated as 59.5%, while this increased to 75.7% within 6 weeks from the diagnosis of hypercalcemia. Survival outcomes are poor after the diagnosis of hypercalcemia in cancer patients. Best supportive care including hospice care should be strongly considered at this point of time instead of definite systemic anti-cancer therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hypercalcemia of malignancy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bisphosphonate therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Squamous cell carcinoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Best supportive care</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arya, Lima</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Saha, Rajat</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Walia, Meenu</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nayak, Priya P</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Indian Journal of Surgical Oncology</subfield><subfield code="d">Springer-Verlag, 2010</subfield><subfield code="g">13(2020), 1 vom: 11. Juni, Seite 28-32</subfield><subfield code="w">(DE-627)SPR030797241</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1</subfield><subfield code="g">day:11</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:28-32</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13193-020-01131-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2020</subfield><subfield code="e">1</subfield><subfield code="b">11</subfield><subfield code="c">06</subfield><subfield code="h">28-32</subfield></datafield></record></collection>
|
| author |
Sundriyal, Deepak |
| spellingShingle |
Sundriyal, Deepak misc Hypercalcemia of malignancy misc Bisphosphonate therapy misc Squamous cell carcinoma misc Best supportive care Hypercalcemia of Malignancy: Time to Pull the Brakes |
| authorStr |
Sundriyal, Deepak |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR030797241 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
Hypercalcemia of Malignancy: Time to Pull the Brakes Hypercalcemia of malignancy (dpeaa)DE-He213 Bisphosphonate therapy (dpeaa)DE-He213 Squamous cell carcinoma (dpeaa)DE-He213 Best supportive care (dpeaa)DE-He213 |
| topic |
misc Hypercalcemia of malignancy misc Bisphosphonate therapy misc Squamous cell carcinoma misc Best supportive care |
| topic_unstemmed |
misc Hypercalcemia of malignancy misc Bisphosphonate therapy misc Squamous cell carcinoma misc Best supportive care |
| topic_browse |
misc Hypercalcemia of malignancy misc Bisphosphonate therapy misc Squamous cell carcinoma misc Best supportive care |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Indian Journal of Surgical Oncology |
| hierarchy_parent_id |
SPR030797241 |
| hierarchy_top_title |
Indian Journal of Surgical Oncology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)SPR030797241 |
| title |
Hypercalcemia of Malignancy: Time to Pull the Brakes |
| ctrlnum |
(DE-627)SPR046686487 (SPR)s13193-020-01131-5-e |
| title_full |
Hypercalcemia of Malignancy: Time to Pull the Brakes |
| author_sort |
Sundriyal, Deepak |
| journal |
Indian Journal of Surgical Oncology |
| journalStr |
Indian Journal of Surgical Oncology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
txt |
| container_start_page |
28 |
| author_browse |
Sundriyal, Deepak Arya, Lima Saha, Rajat Walia, Meenu Nayak, Priya P |
| container_volume |
13 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Sundriyal, Deepak |
| doi_str_mv |
10.1007/s13193-020-01131-5 |
| normlink |
(ORCID)0000-0002-6378-7694 |
| normlink_prefix_str_mv |
(orcid)0000-0002-6378-7694 |
| title_sort |
hypercalcemia of malignancy: time to pull the brakes |
| title_auth |
Hypercalcemia of Malignancy: Time to Pull the Brakes |
| abstract |
Abstract Hypercalcemia of malignancy (HOM) is usually seen in advanced stage and carries a poor prognosis. Survival outcomes are dismal and most of the patients are unable to receive subsequent definite anti-cancer therapy. There is lack of any retrospective or prospective data regarding hypercalcemia of malignancy in Indian population. We aim to describe survival outcomes in hypercalcemia associated with solid organ malignancies. Forty-five patients diagnosed with HOM associated with solid organ malignancies were included in the study. Patients were followed up till death. Clinical features and survival outcomes were noted. Squamous cell carcinoma of head and neck region and lung comprised most of the cases associated with HOM. Most of the patients presented with poor performance status. Median overall survival (OS) was 20 days (2–78 days). Median OS was 35 days (9–58 days) in those who received definite anti-cancer therapy. Four-week mortality rate was estimated as 59.5%, while this increased to 75.7% within 6 weeks from the diagnosis of hypercalcemia. Survival outcomes are poor after the diagnosis of hypercalcemia in cancer patients. Best supportive care including hospice care should be strongly considered at this point of time instead of definite systemic anti-cancer therapy. © Indian Association of Surgical Oncology 2020 |
| abstractGer |
Abstract Hypercalcemia of malignancy (HOM) is usually seen in advanced stage and carries a poor prognosis. Survival outcomes are dismal and most of the patients are unable to receive subsequent definite anti-cancer therapy. There is lack of any retrospective or prospective data regarding hypercalcemia of malignancy in Indian population. We aim to describe survival outcomes in hypercalcemia associated with solid organ malignancies. Forty-five patients diagnosed with HOM associated with solid organ malignancies were included in the study. Patients were followed up till death. Clinical features and survival outcomes were noted. Squamous cell carcinoma of head and neck region and lung comprised most of the cases associated with HOM. Most of the patients presented with poor performance status. Median overall survival (OS) was 20 days (2–78 days). Median OS was 35 days (9–58 days) in those who received definite anti-cancer therapy. Four-week mortality rate was estimated as 59.5%, while this increased to 75.7% within 6 weeks from the diagnosis of hypercalcemia. Survival outcomes are poor after the diagnosis of hypercalcemia in cancer patients. Best supportive care including hospice care should be strongly considered at this point of time instead of definite systemic anti-cancer therapy. © Indian Association of Surgical Oncology 2020 |
| abstract_unstemmed |
Abstract Hypercalcemia of malignancy (HOM) is usually seen in advanced stage and carries a poor prognosis. Survival outcomes are dismal and most of the patients are unable to receive subsequent definite anti-cancer therapy. There is lack of any retrospective or prospective data regarding hypercalcemia of malignancy in Indian population. We aim to describe survival outcomes in hypercalcemia associated with solid organ malignancies. Forty-five patients diagnosed with HOM associated with solid organ malignancies were included in the study. Patients were followed up till death. Clinical features and survival outcomes were noted. Squamous cell carcinoma of head and neck region and lung comprised most of the cases associated with HOM. Most of the patients presented with poor performance status. Median overall survival (OS) was 20 days (2–78 days). Median OS was 35 days (9–58 days) in those who received definite anti-cancer therapy. Four-week mortality rate was estimated as 59.5%, while this increased to 75.7% within 6 weeks from the diagnosis of hypercalcemia. Survival outcomes are poor after the diagnosis of hypercalcemia in cancer patients. Best supportive care including hospice care should be strongly considered at this point of time instead of definite systemic anti-cancer therapy. © Indian Association of Surgical Oncology 2020 |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER |
| container_issue |
1 |
| title_short |
Hypercalcemia of Malignancy: Time to Pull the Brakes |
| url |
https://dx.doi.org/10.1007/s13193-020-01131-5 |
| remote_bool |
true |
| author2 |
Arya, Lima Saha, Rajat Walia, Meenu Nayak, Priya P |
| author2Str |
Arya, Lima Saha, Rajat Walia, Meenu Nayak, Priya P |
| ppnlink |
SPR030797241 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s13193-020-01131-5 |
| up_date |
2024-07-03T23:55:14.430Z |
| _version_ |
1803604107658788864 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR046686487</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230507151028.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220407s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s13193-020-01131-5</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR046686487</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s13193-020-01131-5-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sundriyal, Deepak</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-6378-7694</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hypercalcemia of Malignancy: Time to Pull the Brakes</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Indian Association of Surgical Oncology 2020</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Hypercalcemia of malignancy (HOM) is usually seen in advanced stage and carries a poor prognosis. Survival outcomes are dismal and most of the patients are unable to receive subsequent definite anti-cancer therapy. There is lack of any retrospective or prospective data regarding hypercalcemia of malignancy in Indian population. We aim to describe survival outcomes in hypercalcemia associated with solid organ malignancies. Forty-five patients diagnosed with HOM associated with solid organ malignancies were included in the study. Patients were followed up till death. Clinical features and survival outcomes were noted. Squamous cell carcinoma of head and neck region and lung comprised most of the cases associated with HOM. Most of the patients presented with poor performance status. Median overall survival (OS) was 20 days (2–78 days). Median OS was 35 days (9–58 days) in those who received definite anti-cancer therapy. Four-week mortality rate was estimated as 59.5%, while this increased to 75.7% within 6 weeks from the diagnosis of hypercalcemia. Survival outcomes are poor after the diagnosis of hypercalcemia in cancer patients. Best supportive care including hospice care should be strongly considered at this point of time instead of definite systemic anti-cancer therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hypercalcemia of malignancy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bisphosphonate therapy</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Squamous cell carcinoma</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Best supportive care</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Arya, Lima</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Saha, Rajat</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Walia, Meenu</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nayak, Priya P</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Indian Journal of Surgical Oncology</subfield><subfield code="d">Springer-Verlag, 2010</subfield><subfield code="g">13(2020), 1 vom: 11. Juni, Seite 28-32</subfield><subfield code="w">(DE-627)SPR030797241</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2020</subfield><subfield code="g">number:1</subfield><subfield code="g">day:11</subfield><subfield code="g">month:06</subfield><subfield code="g">pages:28-32</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s13193-020-01131-5</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2020</subfield><subfield code="e">1</subfield><subfield code="b">11</subfield><subfield code="c">06</subfield><subfield code="h">28-32</subfield></datafield></record></collection>
|
| score |
7.402525 |